---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-046028"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:35:31.824157+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics reports Q3 net loss of $7.5M; pro forma cash $37M after Opus acquisition

## Summary
- Net loss $7.5M ($0.29/share) vs net income $5.6M in Q3 2023; revenue $3.9M down from $11.9M.
- Pro forma cash $37M post-merger with Opus Genetics; expects runway into 2026.
- Acquisition of Opus Genetics closed Oct 22; issued 5.2M common shares and 14,145 Series A preferred.
- Pipeline: four data readouts in 2025 including Phase 3 for Phentolamine in presbyopia and dim light.
- Gene therapy candidate OPGx-LCA5 showed visual improvement in 3/3 adult patients; pediatric enrollment Q1 2025.

## SEC filing metadata
- accession: 0001140361-24-046028
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036124046028/0001140361-24-046028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036124046028/ef20038443_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-046028
- JSON: https://secwatch.observer/filing/0001140361-24-046028.json
- Plain text: https://secwatch.observer/filing/0001140361-24-046028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.